Table 1.
Baseline demographic and clinical characteristics of participants according to the treatments.
| Variables | Placebo (n = 51) | BC (n = 51) | p-value |
|---|---|---|---|
| Age (years) | 51 ± 11 | 53 ± 9 | 0.43 |
| Weight (Kg) | 80 ± 11 | 80 ± 12 | 0.94 |
| BMI (Kg/m2) | 29 ± 4 | 29 ± 3 | 0.86 |
| WC (cm) | 97 ± 8 | 99 ± 10 | 0.29 |
| HC (cm) | 107 ± 7 | 105 ± 7 | 0.30 |
| FM (Kg) | 25 ± 8 | 25 ± 7 | 0.80 |
| SBP (mmHg) | 113 ± 17 | 112 ± 14 | 0.97 |
| DBP (mmHg) | 71 ± 14 | 73 ± 11 | 0.70 |
| CAP score (dB/m) | 285 ± 40 | 294 ± 39 | 0.27 |
| IQR | 11 ± 6 | 11 ± 5 | 0.95 |
| Stiffness (kPa) | 5.3 ± 1.4 | 4.9 ± 1.3 | 0.15 |
| IQR | 14 ± 5 | 14 ± 7 | 0.53 |
| Glucose (mg/dL) | 92 ± 8 | 93 ± 8 | 0.74 |
| Insulin (mU/L) | 9.9 ± 4 | 10 ± 5 | 0.84 |
| HOMA-IR | 2.3 ± 1.0 | 2.3 ± 1.2 | 0.74 |
| TC (mg/dL) | 196 ± 39 | 193 ± 39 | 0.66 |
| TG (mg/dL) | 115 ± 48 | 107 ± 53 | 0.42 |
| HDL-C (mg/dL) | 51 ± 13 | 53 ± 12 | 0.48 |
| LDL-C (mg/dL) | 122 ± 34 | 118 ± 34 | 0.60 |
| Non-HDL-C (mg/dL) | 145 ± 36 | 140 ± 39 | 0.49 |
| AST (IU/L) | 23 ± 15 | 21 ± 6 | 0.23 |
| ALT (IU/L) | 32 ± 27 | 23 ± 12 | 0.06 |
| γGT (UI/L) | 27 ± 20 | 25 ± 17 | 0.59 |
| Creatinine (mg/dL) | 0.82 ± 0.1 | 0.83 ± 0.2 | 0.80 |
| Uric Acid (mg/dL) | 5.1 ± 1.1 | 5.2 ± 1.2 | 0.70 |
| Total bilirubin (mg/dL) | 0.61 ± 0.3 | 0.62 ± 0.3 | 0.90 |
| Prevalence | |||
| Gender (Female,%) | 45 | 43 | 1 |
| Menopause (%) | 70 | 68 | 1 |
| Smokers (%) | 12 | 24 | 0.19 |
| Obesity (%) | 41 | 33 | 0.77 |
| MS (%) | 31 | 22 | 0.37 |
| Hypertension (%) | 35 | 37 | 1 |
| Hyperlipidemia (%) | 57 | 49 | 0.55 |
| Antihypertensive drugs (%) | 29 | 31 | 1 |
| Lipid-lowering agents (%) | 10 | 18 | 0.38 |
| Antiplatelet agents (%) | 6 | 10 | 0.71 |
| Liver steatosis S1 grade (%) | 26 | 16 | 0.20 |
| Liver steatosis S2 grade (%) | 35 | 35 | 0.20 |
| Liver steatosis S3 grade (%) | 39 | 49 | |
| Liver Fibrosis (%) | 10 | 6 | 0.71 |
BMI, body mass index; WC, waist circumference; HC, hip circumference; FM, fat mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; CAP, controlled attenuation parameter; IQR, interquartile range; HOMA-IR, homeostatic model assessment of insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma glutamyltransferase.